All stock lists
Haemonetics Corp (New York Stock Exchange:HAE)
US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
120.28+0.14 (+0.12%)
Market cap
$5.47B
Insider Score
Health Score
Analyst consensus
Listed since
May 10, 1991
Website
Insider Score
––Not scored
HAE Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
HAE analyst forecast
HAE analyst consensus
Moderate Buy7 ratings
Buy 6 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
HAE 12-month price target
$132.50+10.2% upsideaverage of 2 firms
$140.00High
$125.00Low
HAE ratings mix, last 12 months
Buy Hold Sell
Best analysts covering HAE
- Raymond James70%success rate · +22.3% avg return · 10 calls
- Mizuho60%success rate · +12.9% avg return · 5 calls
- Citigroup50%success rate · +51.6% avg return · 2 calls
- Barrington Research44%success rate · +7.8% avg return · 18 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
HAE analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-10-09 |
| Mizuho | Outperform | $140.00 | +17.3% | Reiterated | 2026-10-09 | |
| — | BTIG | Buy | — | — | Reiterated | 2026-10-08 |
| — | Citigroup | Buy | — | — | Upgraded | 2026-09-17 |
| Raymond James | Outperform | $125.00 | +21.4% | Reiterated | 2026-09-03 | |
| — | Baird | Outperform | — | — | Reiterated | 2026-08-21 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-08-19 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-18 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-08-07 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-08-07 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-06 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-15 |
| — | BTIG | Buy | — | — | Reiterated | 2026-06-26 |
| — | BTIG | Buy | — | — | Reiterated | 2026-06-17 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-06-15 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-05-28 |
| — | B of A Securities | Buy | — | — | Upgraded | 2026-05-22 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-05-12 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-05-08 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-04-13 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-04-07 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-03-11 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-02-06 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-02-06 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-02-06 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-06 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-02-02 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-01-12 |
| — | BTIG | Buy | — | — | Reiterated | 2026-01-09 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-12-17 |
| — | Baird | Outperform | — | — | Reiterated | 2025-12-15 |
| — | Needham | Hold | — | — | Downgraded | 2025-12-15 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-12-12 |
| — | Citigroup | Neutral | — | — | Downgraded | 2025-12-11 |
| — | BTIG | Buy | — | — | Reiterated | 2025-11-21 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-11-07 |
| — | Needham | Buy | — | — | Reiterated | 2025-11-07 |
| — | BTIG | Buy | — | — | Reiterated | 2025-11-06 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-10-21 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-10-07 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-09-23 |
| — | Raymond James | Outperform | — | — | Downgraded | 2025-08-11 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-08-08 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-08-08 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2025-08-08 |
| — | Needham | Buy | — | — | Reiterated | 2025-08-07 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-07-11 |
| — | Citigroup | Buy | — | — | Upgraded | 2025-07-09 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-05-20 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-05-09 |
| — | Needham | Buy | — | — | Reiterated | 2025-05-08 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-07 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-02-07 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-02-07 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-02-07 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-12-04 |
| — | Needham | Buy | — | — | Reiterated | 2024-12-03 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-15 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-11-08 |
| — | Raymond James | Strong Buy | — | — | Upgraded | 2024-11-08 |
HAE earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-11-06 | 1.12 | 1.27 | $329.8M | $327.3M |
| 2026-02-05 | 1.27 | 1.31 | $331.9M | $339.0M |
| 2026-05-07 | 1.28 | 1.29 | $336.8M | $346.4M |
| 2026-08-06 | 1.08 | 1.14 | $327.9M | $339.4M |
| 2026-11-05Upcoming | 1.29 | — | $345.1M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.